Current Report Filing (8-k)
08 Octobre 2013 - 10:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 8, 2013
MAKO Surgical Corp.
(Exact name of registrant as specified in its charter)
Delaware |
001-33966 |
20-1901148 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
2555 Davie Road
Fort Lauderdale, Florida 33317
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area
code: (954) 927-2044
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.01 |
Completion of Acquisition or Disposition of Assets. |
As previously reported, on October
1, 2013, MAKO Surgical Corp. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”)
with Pipeline Biomedical Holdings, Inc. (“Pipeline”).
On October 8, 2013, pursuant to
the terms of the Purchase Agreement, the Company completed the acquisition of substantially all of Pipeline’s business dedicated
to the design, development, manufacture and commercialization of orthopedic devices and related instruments for use with robotic
devices and manual medical procedures (the “Transaction”).
The purchase price for the Transaction
consisted of a credit for a cash down payment previously paid to Pipeline in the amount of $2,500,000 and the Company’s issuance
at closing to Pipeline of an aggregate of 3,953,771 unregistered shares of common stock of the Company. The Company also entered
into employment and consulting arrangements with certain key employees of the acquired business.
The foregoing description of the
Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which
is filed as Exhibit 2.1 hereto and incorporated herein by reference.
Item 3.02 |
Unregistered Sales of Equity Securities. |
The information set forth above
in Item 2.01 regarding the unregistered sale of shares of common stock of the Company in connection with the Transaction is incorporated
herein by reference.
On October 8, 2013, the Company
issued a press release announcing the closing of the Transaction. A copy of the press release is furnished herewith as Exhibit
99.1 hereto and is incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(a) Audited and Unaudited Financial
Statements of Businesses Acquired:
The Company will file any financial
statements required by Item 9.01(a) by amendment not later than 71 calendar days after the date that this Current Report on Form
8-K is required to be filed.
(b) Pro Forma Financial Information:
The Company will furnish any pro
forma financial information required by Item 9.01(b) by amendment not later than 71 calendar days after the date that this Current
Report on Form 8-K is required to be filed.
(d) Exhibits:
Exhibit 2.1 |
Asset Purchase Agreement, dated October 1, 2013, by and between Pipeline Biomedical Holdings, Inc. and MAKO Surgical Corp. (incorporated by reference to Exhibit 2.1 to Form 8-K filed on October 2, 2013).† |
|
|
Exhibit 99.1 |
Press Release dated October 8, 2013. |
†Schedules and other similar attachments have been
omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of
the omitted schedules and attachments upon request by the U.S. Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
MAKO SURGICAL CORP. |
Date: October 8, 2013 |
|
|
/s/ Maurice R. Ferré, M.D. |
|
Maurice R. Ferré, M.D.
President and Chief Executive Officer |
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025